Search | Clinical Trials Finder

Conditions: Melanoma
Interventions: Single agent, adjuvant anti-PD1 therapy; Drug
Lead sponsor: John Kirkwood; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx Cancer
Interventions: Cemiplimab, Fianlimab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Colorectal Cancer, Gastroesophageal Cancer
Interventions: nivolumab, ipilimumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer (TNBC)
Interventions: NRM-823; Drug
Lead sponsor: Normunity AccelCo, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more

Conditions: Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
Interventions: Nivolumab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
Interventions: Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), Cryoablation; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Cancer
Interventions: AMD3100, Pembrolizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
Interventions: Abemaciclib, Cabozantinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Baltimore, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Head and Neck Cancer
Interventions: NKTR-214, anti-PD-1 therapy, Palliative Radiation; Drug · Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Glioblastoma
Interventions: NeoVax, Nivolumab, Ipilimumab, Research blood draw, Leukapheresis for research; Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm, HIV-associated Cancers
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ipilimumab, Nivolumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 32
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 19 more

Conditions: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Interventions: TT-816, A PD-1 inhibitor; Drug
Lead sponsor: Teon Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Nashville, Tennessee • Austin, Texas • San Antonio, Texas + 2 more

Conditions: Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab; Drug · Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Synovial Sarcoma, Soft Tissue Sarcoma, Undifferentiated Sarcoma
Interventions: T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product; Genetic · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2043
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
Interventions: Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Oligometastatic Prostate Cancer
Interventions: Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: Catherine Spina; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab, Lurbinectedin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Kissimmee, Florida • Tampa, Florida

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
Interventions: Pembrolizumab (immunotherapy), Quad-shot palliative radiotherapy; Drug · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Advanced Solid Tumors
Interventions: mRNA-4359, Pembrolizumab, Ipilimumab, Nivolumab; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation, U2AF1 Gene Mutation, SRSF2 Gene Mutation
Interventions: Recommendation for treatment with immunotherapy; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Urothelial Carcinoma
Interventions: Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily + atezolizumab 1200 mg, Derazantinib 200 mg twice daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily monotherapy (QD), Derazantinib 200 mg twice daily monotherapy; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more

Conditions: Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma, Soft Tissue Sarcoma, Ovarian Adenocarcinoma, Advanced Well-differentiated Neuroendocrine Tumors, Diffuse Large B Cell Lymphoma
Interventions: PDR001, LAG525; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: San Francisco, California • Port Saint Lucie, Florida • Athens, Georgia + 15 more

Conditions: Melanoma
Interventions: Lerapolturev, Anti-PD-1 Checkpoint Inhibitor; Biological
Lead sponsor: Istari Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 12
States / cities: Scottsdale, Arizona • Orlando, Florida • Chicago, Illinois + 9 more

Conditions: Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Carboplatin, Cisplatin, Docetaxel, Ipilimumab, Nivolumab, Pemetrexed; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)

CIML NK Cell in Head & Neck Cancer

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer